drugset / Trial / NCT07275840
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
NaSingle-groupOpen-labelTreatment
Summary
This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.
Timeline
- Start
- 2025-12-05
- Primary completion
- 2026-08-30
- Completion
- 2026-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI302 | Unknown | 8 mg | Intravitreal |